lumateperone

6 Neuro Data Readouts to Watch in the First Half of 2024
BioSpace
Mon, 01/22/24 - 11:53 am
neurodegenerative disease
clinical trials
ALS
major depressive disorder
Huntington's disease
Sanofi
Denali Therapeutics
Intra-Cellular Therapies
lumateperone
Annexon Biosciences
Guillain-Barré Syndrome
ANX005
Wave Life Sciences
Praxis Precision Medicines
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
5 FDA approval decisions to watch in the fourth quarter
BioPharma Dive
Sun, 10/3/21 - 08:32 pm
FDA
vaccines
COVID-19
Pfizer
BioNTech
JNJ
cilta cel
Biomarin
vosoritide
Intra-Cellular Therapies
lumateperone
Moderna Therapeutics
Intra-Cellular Bipolar Drug Shows "Significant" Benefit in Depressive Episodes
BioSpace
Tue, 09/28/21 - 11:10 am
Intra-Cellular Therapies
clinical trials
lumateperone
bipolar disorder
Intra-Cellular roars back on success in bipolar depression
BioPharma Dive
Wed, 09/9/20 - 08:07 pm
Intra-Cellular Therapeutics
bipolar disorder
lumateperone
clinical trials
Intra-Cellular approval keeps focus on FDA's neuroscience review process
BioPharma Dive
Thu, 12/26/19 - 01:05 pm
FDA
Intra-Cellular Therapies
lumateperone
schizophrenia
Caplyta
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Mon, 12/16/19 - 10:52 am
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
3 Biotechs Facing FDA Approvals by Year's End
Motley Fool
Mon, 12/9/19 - 09:45 am
FDA
Amgen
Vascepa
Allergan
migraines
ubrogepant
Intra-Cellular Therapies
lumateperone
schizophrenia
4 FDA Dates Biotech Investors Should Circle in December
Motley Fool
Sun, 12/8/19 - 10:24 pm
FDA
Amgen
anti-inflammatories
ABP710
Bausch Health Companies
acne
IDP-123
Intra-Cellular Therapies
lumateperone
schizophrenia
Vascepa
Amarin
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Wed, 11/27/19 - 12:43 pm
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble
Stat
Tue, 07/23/19 - 07:41 pm
Intra-Cellular Therapies
FDA
advisory panels
schizophrenia
lumateperone
Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results
BioCentury
Mon, 07/8/19 - 08:16 pm
Intra-Cellular Therapies
lumateperone
clinical trials
bipolar disorder
FDA Clears Way for Filing on Psych Drug From Intra-Cellular, Shares Climb
Xconomy
Wed, 08/23/17 - 11:19 am
FDA
Intra-Cellular Therapies
lumateperone
schizophrenia